ATLAS fair value
ATLAS has no fair value for this stock today.
Infant Bacterial Therapeutics AB (publ) stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · Nasdaq Stockholm · Sweden
Prices as of Oct 27, 2026 · SEK
ATLAS has no fair value for this stock today.
48%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS's model gives Infant Bacterial Therapeutics AB (publ) a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between SEK 59.64 and SEK 72.06; in 9 out of 10, between SEK 50.44 and SEK 85.21. Estimated annual volatility is 53%.
ATLAS does not publish a fair value for IBT-B.ST right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks IBT-B.ST has traded between SEK 43.25 and SEK 84.90. Today it is 22.3% below that high and 53% above its low.
Its beta is 0.32: it tends to move less than the market.
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden.
Want to see everything about Infant Bacterial Therapeutics AB (publ)?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden.
48%: close to a coin flip. In half of the simulated outcomes, IBT-B.ST ends the month between SEK 59.64 and SEK 72.06.
Infant Bacterial Therapeutics AB (publ)'s market capitalization is SEK 1.1B. We do not show a P/E because it has no positive earnings to base one on.
ATLAS estimates annual volatility at 53%. In a typical month, half of the outcomes end between SEK 59.64 and SEK 72.06.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy